Are there regional variations in the presentation of childhood leukemia?

Klerize de Souza Silva, Ciliana Rechenmacher, Rahuany Velleda de Morais, Mariana Bohns Michalowski, Liane Esteves Daudt

Abstract


Introduction: Treatment of childhood acute lymphoblastic leukemia (ALL) is based
on risk stratification. This study aimed to assess the agreement between risk group
classifications in the different childhood ALL treatment protocols used in a referral
hospital in southern Brazil.
Methods: We retrospectively reviewed the medical records of patients aged 1 to
18 years with B-cell ALL treated at a hospital from January 2013 to April 2017. Agreement
between risk classifications was assessed by the kappa coefficient.
Results: Seventy-five patients were analyzed. There was poor agreement between
risk stratification by GBTLI 2009 and BFM 95 protocols (kappa=0.22; p = 0.003) and
by GBTLI 2009 and IC-BFM 2002 protocols (kappa=0.24; p = 0.002). Risk group
distribution was 13.3% for low risk, 32.0% for intermediate risk, and 54.7% for high
risk based on stratification by the GBTLI 2009 protocol, and 28.0% for low risk, 42.7%
for intermediate risk, and 29.3% for high risk based on stratification by the IC-BFM
2002 protocol. Overall survival was 68.6%.
Conclusion: This study provides numerous points to ponder about the treatment
of leukemia in Brazil. The percentage of patients classified as high risk in our
sample was higher than that reported in the international literature. This difference,
however, had no impact on overall survival, which was shorter than that reported
in the international literature.


Keywords


childhood ALL; risk factors; immunophenotyping; minimal residual disease.

Full Text:

PDF


Copyright (c) 2021 Clinical & Biomedical Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN: 2357-9730 

http://seer.ufrgs.br/hcpa/

 

 

Apoio Financeiro:

 


Licença Creative Commons
The Clinical & Biomedical Research is licenced under Creative Commons Atribuição 4.0 Internacional.